DiscoveRx Corporation Release: Comprehensive PathHunter® Assay Portfolio Driving Antibody Therapeutic Discovery Programs
5/1/2012 9:13:53 AM
FREMONT, Calif.--(BUSINESS WIRE)--DiscoveRx Corporation, a global provider of innovative assay solutions used in assay development, drug screening and profiling, announced that its PathHunter assays are gaining widespread adoption in large molecule therapeutic discovery campaigns and especially for discovery, characterization and functional QC of antibody therapeutics. In the last 5 years, therapeutics discovery has continued to move toward large molecules and biologics for drug development, in areas previously dominated by small molecules. Now, the scientific community has access to over 400 PathHunter GPCR, Kinase and signaling bio-assays to expedite discovery of neutralizing, blocking or activating antibodies. This proven platform exhibits unparalleled specificity, reliability and sensitivity compatible with a variety of antibody samples such as phage supernatants, sera and hybridoma culture.
comments powered by